The Inserm spinout secured a $7.8m series B extension and boosted its portfolio with the acquisition of AVCare, a Satt Ouest Valorisation-allied business.

Acticor Biotech, a France-based acute thrombotic disease therapeutics spinout of research institute Inserm, closed a €22.3m ($24.7m) series B round yesterday with a $7.8m extension led by regional investment unit Go Capital.
The extension also featured life sciences-focused venture fund Newton Biocapital, VC firm CapDecisif Management and investment platform Anaxago, adding to an initial $17m series B sum announced in October 2018.
Newton BioCapital led the initial tranche with participation from financial services firm Mirae Asset Capital, CapDecisif…